NEWS_NEWS_企业官网

Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

TAVOTEK BIOTHERAPEUTICS ANNOUNCES FORMATION AND MEMBERS OF SCIENTIFIC ADVISORY BOARD

 发布时间 : 2022-04--25  点击量 : 0

(LOWER GWYNEDD, Pennsylvania, April 25, 2022) Tavotek Biotherapeutics, a fast-growing biopharmaceutical company focusing on discovering and developing therapeutic medicines, announced the formation of a Scientific Advisory Board (SAB) comprised of scientific and industry leaders in oncology and immunology. The SAB will work cohesively with Tavotek to advance the company’s discovery and clinical pipelines. “The distinguished group of industry experts and scientific leaders that we have assembled will provide Tavotek with excellent guidance in the years to come,” said Mark Chiu, Ph.D., President and CSO of Tavotek. “Each member brings deep, internationally recognized expertise and experience in cutting-edge technology, protein engineering, and deep knowledge in oncology and immunology for early- to late-stage development of innovative therapeutics. We have already received valuable feedback from our first meeting, and I believe this collection of intellect and experience will continue to energize Tavotek to advance our proprietary technology platforms to develop innovative assets.” Members of the Tavotek Scientific Advisory Board include: About Tavotek Tavotek is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. For more information, please visit www.tavotek.com. Tavotek Contact: Isa Fung, Investors and Media Relations Email: BD@tavotek.com

TAVOTEK LAUNCHING FIRST-IN-HUMANSTUDY OF 3 ASSETS IN 2022

 发布时间 : 2022-04--07  点击量 : 0

(LOWER GWYNEDD, Pennsylvania, April 5, 2022) Tavotek Biotherapeutics announced today that its first pipeline biologic asset, TAVO103A, had been successfully dosed in two human subjects in the ICON Phase 1 Clinical Trial Center in Salt Lake City, Utah. TAVO103A is a best-in-class human monoclonal antibody developed for chronic inflammation. This study, termed TAVO103A-0001, is a double-blind, randomized, placebo-controlled Phase 1 evaluation of the safety, tolerability, immunogenicity, and PK/PD of TAVO103A in human volunteer subjects. The US IND was filed in late December 2021 and was approved by the FDA in January 2022. Meanwhile, the IND of another biologic, TAVO101, has also been approved for human testing in Australia in January 2022 at the CMAX Phase 1 Clinical Trial Center in Adelaide, Australia. TAVO101 is also a best-in-class human monoclonal antibody developed for allergic diseases. The study, termed TAVO101-0001, is also a double-blind, randomized, placebo-controlled Phase 1 study. The study site is actively screening subjects for first-in-human dosing that will occur soon. Dr. Mann Fung, CEO of Tavotek stated, “Today is a historic moment for Tavotek, not only because our pipeline asset was first dosed in the human subjects, but this also officially transforms Tavotek from a preclinical company to a clinical-stage company. We are eager to bring our innovative assets to patients with unmet medical needs.” “We are excited for the great progress that Tavotek has made over the past few years, “ said Dr. Mark Chiu, CSO of Tavotek. “Besides immunology assets, our first-in-class multispecific antibody for patients with solid tumors, TAVO412, is in late stage of preclinical development. We plan to file an IND to the US FDA and start human dosing in the second half of 2022. We are very excited and proud of our accomplishments.” About Tavotek Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. For more information, please visit www.tavotek.com. Tavotek Contact: Isa Fung, Investors and Media Relations Email: info@tavotek.com

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

 发布时间 : 2021-11--18  点击量 : 0

LOWER GWYNEDD, Penn., Nov. 18, 2021 /PRNewswire/ -- Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addition, the funding will also be used to accelerate the CMC and IND development of multiple other oncology pipelines and the development of the company's multicyclic intracellular peptide (MIP) programs. Tavotek Biotherapeutics, established in early 2019, is committed to using innovation to improve the well-being of patients with unmet medical needs. The company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China. The core team members have decades of successful drug development experiences at multinational pharmaceutical firms (Johnson & Johnson, Abbott/Abbvie, GlaxoSmithKline and Eli Lilly) which include many blockbuster drugs with annual sales of more than $1 billion. Tavotek's research platforms are built upon three breakthrough technologies: TavoSelect (an innovative Phage Display Library that generates conformational selective human full-length and single domain antibodies); TavoPrecise (a differentiated engineering platform for next generation tissue-specific biologics); and TavoMIP (a multicyclic peptide platform that makes undruggable targets more accessible). With the new infusion of capital, Tavotek is developing novel biologics targeting oncology and autoimmune diseases for patients. The company plans to bring multiple innovative antibodies into human clinical trials in 2022. About Tavotek Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. For more information, please visit www.tavotek.com. Tavotek Contact: Vicky Wu, External Affairs Email: vicky.wu@tavotek.com Isa Fung, Investors and Media Email: info@tavotek.com SOURCE Tavotek Biotherapeutics

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

 发布时间 : 2021-08--17  点击量 : 0

CHEYNEY, Pa. and AMBLER, Pa., Aug. 17, 2021 /PRNewswire/ -- Navrogen Inc. ("Navrogen"), a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics ("Tavotek"), a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will collaborate on the development of future Tavotek oncology assets while utilizing Navrogen's proprietary screening technology to identify mAb leads that are susceptible to Humoral Immuno-Oncology (HIO) factors. HIO is a process by which tumors produce factors that suppress a patient's humoral immune response against malignant tissues as well as diminish therapeutic response of immune-mediated anti-cancer therapies. Working with Navrogen's HIO platform technologies and its expertise in patient tumor screening methods, the teams will identify and/or engineer HIO-refractory antibodies that are effective across a wide range of HIO-positive cancers leading to innovative treatment options for patients with limited therapeutic options. About Navrogen™ Inc Navrogen is a biopharmaceutical company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity, poor prognosis and limited therapeutic response of immune-mediated anti-cancer therapies. The company's mission is to develop first-in-class agents that can overcome the immunosuppressive effects of HIO factors by employing its proprietary screening and engineering technologies as well as diagnostic assays that can identify patients whose tumors produce HIO factors to advise physicians on therapeutic options. For more information, please visit www.navrogen.com. About Tavotek Biotherapeutics Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. For more information, please visit www.tavotek.com. Contacts: Navrogen Inquiries: Tavotek Inquiries: Steve Kyriakos Isa Fung 610-399-2718 267-405-9426 steve@navrogen.com isa.fung@tavotek.com SOURCE Navrogen, Incorporated Related Links http://navrogen.com/

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND A1 AND A2 FINANCING WITH OVER $20 MILLION DOLLARS

 发布时间 : 2021-03--22  点击量 : 0

Tavotek Biotherapeutics announces it has raised over $20M in Round A1 and Round A2 financing in the preceding two months. YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital. Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital. The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody platform. In addition, the funding will also be used to strengthen its bispecific / multispecific antibody pipelines and the development of multicyclic intracellular peptide (MIP) programs.

TAVOTEK BIOTHERAPEUTICS ANNOUNCES A RESEARCH AGREEMENT WITH GENMAB FOR THE DEVELOPMENT OF BISPECIFIC ANTIBODIES USING GENMAB’S PROPRIETARY DUOBODY® TECHNOLOGY PLATFORM AGAINST A PAIR OF DISEASE RELEVANT TARGETS

 发布时间 : 2020-05--25  点击量 : 0

Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab’s DuoBody®technology platform against disease relevant target antigens. Tavotek employs TavoSelectTM, with proprietary VHO phage and Fab phage libraries, to efficiently identify lead molecules for generation of bispecific antibodies against validated target combinations. The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions.

YISHENG BIOPHARMA AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC RESEARCH ALLIANCE FOR DEVELOPMENT OF YS-ON-001/002 AND TAVO-301/303 COMBINATION THERAPY FOR CANCER TREATMENT

 发布时间 : 2020-01--06  点击量 : 0

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that the companies have entered into a strategic research alliance and collaborate in the development involving their lead assets in oncology. The objective of the alliance is to co-develop a combination therapy of YS-ON-001/002 and Tavo-301/303 for cancer treatment. The two companies are also in discussions regarding additional research and development collaborations beyond oncology.